The invention relates to 5-HT receptor agonists and partial agonists. Novelthienopyridinone compounds represented by Formula I, and synthesis and usesthereoffor treating diseases mediated directly or indirectly by 5-HT receptors, aredisclosed.Such conditions include Alzheimer's disease, cognition disorders, irritablebowelsyndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal refluxdisease,nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine,arrhythmia,atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders,feeding disorders,gastrointestinal disorders, constipation, erectile dysfunction, andrespiratory depression.Methods of preparation and novel intermediates and pharmaceutical saltsthereof are alsoincluded.(see formula I)
